Find Clinical Trial

A Multi-center, Open-label, Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To >65 Years with Newly-diagnosed Philadelphia-negative ALL


← Back
Study Phase

Phase 2-3

Therapeutic Area

Cancers

IndicationBlood cancer
SponsorInstitut de Recherches Internationales Servier (I.R.I.S.)
Active substance/
Medical device

Calaspargase pegol,
S095015

Active Substance CodeS095015
Protocol CodeCL2-95015-001
NCT CodeNCT04817761




Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2021 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility